Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 5/20 | 0.52 |
| ▸ | BCHE | P06276 | 4/20 | 0.52 |
| ▸ | MAOA | P21397 | 4/20 | 0.52 |
| ▸ | ACHE | P22303 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 4/20 | 0.51 |
| ▸ | ANPEP | P15144 | 3/20 | 0.49 |
| ▸ | MMP2 | P08253 | 2/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14409418 | 0.83 | HRH3 (0.66) | KMT2AKDM4EALDH1A1TDP1ACHE | |
| SCHEMBL5217334 | 0.83 | HRH3 (0.66) | KMT2AKDM4EALDH1A1TDP1ACHE | |
| SCHEMBL5958484 | 0.82 | HRH3 (0.65) | KMT2AKDM4EALDH1A1TDP1MAOB | |
| SCHEMBL14409349 | 0.82 | HRH3 (0.65) | KMT2AKDM4EALDH1A1TDP1MAOB | |
| SCHEMBL5225111 | 0.79 | HRH3 (0.69) | KMT2AALDH1A1 | |
| SCHEMBL5220948 | 0.79 | HRH3 (0.70) | KMT2AALDH1A1PTGS2 | |
| SCHEMBL14409466 | 0.79 | HRH3 (0.70) | KMT2AALDH1A1PTGS2 | |
| SCHEMBL31452775 | 0.78 | APP (0.63) | KMT2AKDM4EALDH1A1TDP1L3MBTL1 | |
| SCHEMBL5218921 | 0.73 | MAPT (0.56) | KMT2AKDM4EALDH1A1MAOBACHE | |
| SCHEMBL13515512 | 0.72 | HRH3 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1474419-B1 | AMIDES OF AMINOALKYL-SUBSTITUTED AZETIDINES, PYRROLIDINES, PIPERIDINES AND AZEPANES | NOVO NORDISK AS (DK) | 2007-09-05 | — | — | EP | disclosed |
| US-7101898-B2 | For therapy of allergic rhinitis, ulcer or anorexia, diabetes, Alzheimer's disease, narcolepsy or attention deficit disorder | NOVO NORDISK A/S (DK) | 2006-09-05 | — | — | US | disclosed |
| US-20030195190-A1 | Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes | HIGH POINT PHARMACEUTICALS, LLC | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195190-A1 | Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes | HRH3, HRH2, HRH4 | KMT2A 441/4885KDM4E 690/4885ALDH1A1 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.